Health

1 article in this topic.

• Moderna Shares Drop Up to 25% as Leaked Melanoma Vaccine Data Show 42% Risk CutModerna's personalized melanoma vaccine, paired with Merck's Keytruda, cut the risk of cancer returning or death by 42% in a 1,137-patient Phase 3 trial, yet the stock fell as much as 25% after the data leaked two days early.Oct 22, 2026